Clinical trial · Observational
Sentinel Lymph Node Biopsy in Patients With Early Stages Cervical Cancer
A Prospective Observational Trial on Sentinel Lymph Node Biopsy in Patients With Early Stage Cervical Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To evaluate whether a less radical surgical approach with sentinel lymph node biopsy is non-inferior to treatment with systematic pelvic lymphadenectomy. The null hypothesis is that the recurrence rate after SLN biopsy is non-inferior to the reference recurrence rate of 7 % (at the 24th month of follow-up) in patients after systematic pelvic lymphadenectomy, but that the less radical surgery is associated with significantly lower postoperative morbidity.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Cancer | Malignant Cervical Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| At least unilateral systematic pelvic lymph node dissection | Procedure | — | UNRESOLVED |
| Sentinel lymph node biopsy | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Sentinel lymph node (SLN)
- description
- Only sentinel lymph node biopsy, no further pelvic lymph nodes removal, radical hysterectomy.
- interventionNames
- Procedure: Sentinel lymph node biopsy
- label
- Control
- description
- Control group is composed by either those who were enrolled into the trial, but who did not fulfil intra-operative criteria (especially failure to detect SLN on both pelvic side walls) or those in whom systematic lymphadenectomy is planned upfront.
- interventionNames
- Procedure: At least unilateral systematic pelvic lymph node dissection
Primary outcomes (1)
- measure
- Recurrence rate at the 24th month of follow-up (cervical recurrences after fertility-sparing procedures will be excluded)
- timeFrame
- 24 months
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
I) SLN study group: Inclusion criteria: A) Preoperative: 1. FIGO stage IA1+LVSI; IA2; IB1 2. No evidence of bulky or suspicious pelvic lymph nodes or distant metastases in preoperative conventional imaging studies 3. Performance status ECOG: 0 - 1 4. Age ≥ 18 years, ≤ 75 years 5. Squamous cell carcinoma OR Adenocarcinoma usual type (HPV related) 6. Suitable candidates for primary surgical treatment such as: * radical hysterectomy in tumors ≤ 4 cm in the largest diameter OR * fertility-sparing treatment in tumors ≤ 2 cm in the largest diameter 7. History of second primary cancer only if \> 5 years with no evidence of disease 8. Approved and signed Informed consent B) Intra-operative 1. Bilateral SLN detection 2. Negative intra-operative pathologic SLN evaluation (frozen section) 3. No intra-operative evidence of more advanced disease (\>IB1) Exclusion Criteria: 1. Neoadjuvant chemotherapy 2. Pregnancy 3. History of pelvic or abdominal radiotherapy 4. HIV positivity / AIDS 5. Adenosquamous cancer or adenocarcinoma unusual type (non HPV related - such as: mucinous, clear cell, mesonephric) II) Control Group: Inclusion criteria: A) Preoperative: 1. FIGO stage IA1 + LVSI; IA2; IB 2. Performance status ECOG: 0-1 3. Age ≥ 18 years, ≤ 75 years 4. Patient is not pregnant 5. No history of pelvic or abdominal radiotherapy 6. Patient scheduled for surgical treatment including systematic pelvic lymphadenectomy 7. Approved and signed Informed Consent B) Intra-operative: a) Systematic pelvic lymphadenectomy performed at least on one side of the pelvis Exclusion criteria: 1. Pregnancy 2. History of pelvic or abdominal radiotherapy
References
Publications (15)
- BACKGROUNDZikan M, Fischerova D, Pinkavova I, Slama J, Weinberger V, Dusek L, Cibula D. A prospective study examining the incidence of asymptomatic and symptomatic lymphoceles following lymphadenectomy in patients with gynecological cancer. Gynecol Oncol. 2015 May;137(2):291-8. doi: 10.1016/j.ygyno.2015.02.016. Epub 2015 Feb 24. PMID 25720294
- BACKGROUNDCibula D, Oonk MH, Abu-Rustum NR. Sentinel lymph node biopsy in the management of gynecologic cancer. Curr Opin Obstet Gynecol. 2015 Feb;27(1):66-72. doi: 10.1097/GCO.0000000000000133. PMID 25502426
- BACKGROUNDGiammarile F, Bozkurt MF, Cibula D, Pahisa J, Oyen WJ, Paredes P, Olmos RV, Sicart SV. The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1463-77. doi: 10.1007/s00259-014-2732-8. Epub 2014 Mar 8. PMID 24609929
- BACKGROUNDCibula D, Abu-Rustum NR, Dusek L, Slama J, Zikan M, Zaal A, Sevcik L, Kenter G, Querleu D, Jach R, Bats AS, Dyduch G, Graf P, Klat J, Meijer CJ, Mery E, Verheijen R, Zweemer RP. Bilateral ultrastaging of sentinel lymph node in cervical cancer: Lowering the false-negative rate and improving the detection of micrometastasis. Gynecol Oncol. 2012 Dec;127(3):462-6. doi: 10.1016/j.ygyno.2012.08.035. Epub 2012 Aug 31. PMID 22943880
- BACKGROUNDCibula D, Abu-Rustum NR, Dusek L, Zikan M, Zaal A, Sevcik L, Kenter GG, Querleu D, Jach R, Bats AS, Dyduch G, Graf P, Klat J, Lacheta J, Meijer CJ, Mery E, Verheijen R, Zweemer RP. Prognostic significance of low volume sentinel lymph node disease in early-stage cervical cancer. Gynecol Oncol. 2012 Mar;124(3):496-501. doi: 10.1016/j.ygyno.2011.11.037. Epub 2011 Nov 25. PMID 22120175
- BACKGROUNDCibula D, Abu-Rustum NR, Benedetti-Panici P, Kohler C, Raspagliesi F, Querleu D, Morrow CP. New classification system of radical hysterectomy: emphasis on a three-dimensional anatomic template for parametrial resection. Gynecol Oncol. 2011 Aug;122(2):264-8. doi: 10.1016/j.ygyno.2011.04.029. Epub 2011 May 17.